Nespo

RSS

Withdrawn

This medicine's authorisation has been withdrawn

darbepoetin alfa
MedicineHumanWithdrawn

Swedish is available via eTranslation, the European Commission's machine translation service.

Translate to Swedish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 8 June 2001 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Nespo, darbepoetin alfa, which had been approved for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients and treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. 

The marketing authorisation holder (MAH) responsible for Nespo was Dompé Biotec S.p.A. The European Commission was notified by letter dated 10 November 2008 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Nespo for commercial reasons. 

On 5 December 2008 the European Commission issued a decision to withdraw the marketing authorisation for Nespo. 

Pursuant to this decision the European Public Assessment Report for Nespo is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (427.41 KB - PDF)

Visa

español (ES) (265.94 KB - PDF)

Visa

čeština (CS) (405.67 KB - PDF)

Visa

dansk (DA) (265.54 KB - PDF)

Visa

Deutsch (DE) (266.85 KB - PDF)

Visa

eesti (ET) (265.84 KB - PDF)

Visa

ελληνικά (EL) (427.54 KB - PDF)

Visa

français (FR) (266.83 KB - PDF)

Visa

italiano (IT) (268.66 KB - PDF)

Visa

latviešu (LV) (413.33 KB - PDF)

Visa

lietuvių (LT) (380.87 KB - PDF)

Visa

magyar (HU) (399.21 KB - PDF)

Visa

Malti (MT) (410.13 KB - PDF)

Visa

Nederlands (NL) (265.59 KB - PDF)

Visa

polski (PL) (414.04 KB - PDF)

Visa

português (PT) (268.95 KB - PDF)

Visa

română (RO) (374.99 KB - PDF)

Visa

slovenčina (SK) (401.7 KB - PDF)

Visa

slovenščina (SL) (392.39 KB - PDF)

Visa

suomi (FI) (305.78 KB - PDF)

Visa

svenska (SV) (265.47 KB - PDF)

Visa

Product information

български (BG) (7.33 MB - PDF)

Visa

español (ES) (3.86 MB - PDF)

Visa

čeština (CS) (5.01 MB - PDF)

Visa

dansk (DA) (3.72 MB - PDF)

Visa

Deutsch (DE) (3.87 MB - PDF)

Visa

eesti (ET) (3.39 MB - PDF)

Visa

ελληνικά (EL) (7.83 MB - PDF)

Visa

français (FR) (3.88 MB - PDF)

Visa

italiano (IT) (3.84 MB - PDF)

Visa

latviešu (LV) (5.58 MB - PDF)

Visa

lietuvių (LT) (4.9 MB - PDF)

Visa

magyar (HU) (4.37 MB - PDF)

Visa

Malti (MT) (4.83 MB - PDF)

Visa

Nederlands (NL) (3.86 MB - PDF)

Visa

polski (PL) (5.93 MB - PDF)

Visa

português (PT) (3.86 MB - PDF)

Visa

română (RO) (5.26 MB - PDF)

Visa

slovenčina (SK) (4.59 MB - PDF)

Visa

slovenščina (SL) (4.04 MB - PDF)

Visa

suomi (FI) (3.61 MB - PDF)

Visa

svenska (SV) (3.55 MB - PDF)

Visa
Latest procedure affecting product information:II/0047
28/10/2008
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (388.89 KB - PDF)

Visa

español (ES) (248.4 KB - PDF)

Visa

čeština (CS) (359.84 KB - PDF)

Visa

dansk (DA) (245.89 KB - PDF)

Visa

Deutsch (DE) (244.7 KB - PDF)

Visa

eesti (ET) (246.35 KB - PDF)

Visa

ελληνικά (EL) (369.59 KB - PDF)

Visa

français (FR) (248.5 KB - PDF)

Visa

italiano (IT) (246.05 KB - PDF)

Visa

latviešu (LV) (362.35 KB - PDF)

Visa

lietuvių (LT) (341.15 KB - PDF)

Visa

magyar (HU) (360.85 KB - PDF)

Visa

Malti (MT) (371.87 KB - PDF)

Visa

Nederlands (NL) (246.7 KB - PDF)

Visa

polski (PL) (368.01 KB - PDF)

Visa

português (PT) (245.61 KB - PDF)

Visa

română (RO) (343.92 KB - PDF)

Visa

slovenčina (SK) (356.54 KB - PDF)

Visa

slovenščina (SL) (310.69 KB - PDF)

Visa

suomi (FI) (242.85 KB - PDF)

Visa

svenska (SV) (244.24 KB - PDF)

Visa

Product details

Name of medicine
Nespo
Active substance
darbepoetin alfa
International non-proprietary name (INN) or common name
darbepoetin alfa
Therapeutic area (MeSH)
  • Kidney Failure, Chronic
  • Anemia
  • Cancer
Anatomical therapeutic chemical (ATC) code
B03XA02

Pharmacotherapeutic group

Antianemic preparations

Therapeutic indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Authorisation details

EMA product number
EMEA/H/C/000333
Marketing authorisation holder
Dompé Biotec S.p.A.

Via San Martino 12
I-20122 Milan
Italy

Marketing authorisation issued
08/06/2001
Withdrawal of marketing authorisation
05/12/2008
Revision
19

Assessment history

This page was last updated on

Share this page